Published in Hepatitis Weekly, May 4th, 2009
"Ninety of those subjects were randomly selected to receive concomitant treatment with lamivudine 100 mg/d. The coprimary and end points were the subjects virologic (hepatitis B virus deoxyribonucleic acid [HBV DNA] < 60 IU/mL) and biochemical (normaliazation of alanine aminotransferase levels)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly